All this information, together with the fact that MUC13 has been reported to be overexpressed in several cancers, detected in the serum of patients with various cancers, and associated with increased cancer plasticity and the development of chemoresistance [33, 34], makes it a novel and interesting membrane protein target for detecting the presence of residual tumour cells after CRS-HIPEC treatment. This evidence concerns the gene MUC13 and neoplasm.